ICCM vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ICCM presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum. While the company shows strong top-line revenue growth of 46.20% and maintains a healthy current ratio of 2.61 with minimal debt, these are overshadowed by catastrophic price decay (-71.9% over 1 year) and severe operating losses (-329.63% margin). The disconnect between the current price ($0.32) and the analyst target ($2.73) suggests a speculative bet on future medical device adoption rather than current fundamental value.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ICCM vs JNJ: Head-to-Head Comparison
This page compares IceCure Medical Ltd (ICCM) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.